XML 77 R66.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE DISCLOSURES (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jan. 31, 2019
May 31, 2018
Apr. 30, 2018
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Fair Values Inputs Assets Quantitative Information [Line Items]            
Payments to Acquire Intangible Assets       $ 18,510 $ 0  
Convertible Debt, Current       114,150   $ 112,463
Finite-Lived Intangible Assets, Gross       306,725   288,215
Inventory, Raw Materials, Gross       $ 29,750   27,671
Measurement Input, Discount Rate [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Fair Values Inputs Discount Rate       15.00%    
Interest rate swap [Member] | Delayed Draw Term Loan [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Interest Rate Derivative Liabilities, at Fair Value       $ 1,500    
Impax Laboratories, Inc. [Member] | Equipment [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Finite-Lived Intangible Assets, Gross     $ 58      
Finite-Lived Intangible Asset, Useful Life     5 years      
Fair Value, Inputs, Level 1 [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Notes Payable, Fair Value Disclosure       130,300    
Term Loan [Member] | Senior Secured Credit Facility [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Long-term Debt, Gross       71,300   72,200
Term Loan [Member] | Interest rate swap [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Interest Rate Derivative Liabilities, at Fair Value       1,200    
Abbreviated New Drug Applications [Member] | IDT Australia Limited [Member] | Maximum [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Fair Values Inputs Discount Rate     15.00%      
Abbreviated New Drug Applications [Member] | IDT Australia Limited [Member] | Minimum [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Fair Values Inputs Discount Rate     10.00%      
Abbreviated New Drug Applications [Member] | Impax Laboratories, Inc. [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Payments to Acquire Intangible Assets   $ 2,300        
Finite-Lived Intangible Assets, Gross   $ 1,000        
Finite-Lived Intangible Asset, Useful Life   10 years        
Acquisition Costs Capitalized   $ 100        
Contingent Consideration In An Asset Purchase   $ 10,000        
Abbreviated New Drug Applications [Member] | Impax Laboratories, Inc. [Member] | Maximum [Member] | Measurement Input, Discount Rate [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Fair Values Inputs Discount Rate   15.00%        
Abbreviated New Drug Applications [Member] | Impax Laboratories, Inc. [Member] | Minimum [Member] | Measurement Input, Discount Rate [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Fair Values Inputs Discount Rate   10.00%        
Acquired New Drug Applications [Member] | IDT Australia Limited [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Payments to Acquire Intangible Assets     $ 2,700      
Finite-Lived Intangible Assets, Gross     $ 2,500      
Finite-Lived Intangible Asset, Useful Life     10 years      
Acquisition Costs Capitalized     $ 18      
Inventory, Raw Materials, Gross     $ 200      
Acquired ANDA Intangible Assets [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Finite-Lived Intangible Assets, Gross       $ 64,704   $ 46,194
Finite-Lived Intangible Asset, Useful Life       10 years    
Fair Values Inputs Discount Rate       15.00%    
In Process Research and Development [Member] | Impax Laboratories, Inc. [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Research and Development in Process   $ 1,300        
In Process Research and Development [Member] | Impax Laboratories, Inc. [Member] | Measurement Input, Discount Rate [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Fair Values Inputs Discount Rate   75.00%        
Teva Pharmaceuticals USA, Inc. ("Teva") [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Payments to Acquire Intangible Assets $ 16,000          
Fair Values Inputs Discount Rate 12.00%          
Cumulative Amortization Expense $ 6,800          
Additional Net Carrying Value Added To Finite Lived Intangible Assets Acquired $ 9,200          
Teva Pharmaceuticals USA, Inc. ("Teva") [Member] | Milestone One [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Contingent Liability Not Recognized   $ 25,000        
Teva Pharmaceuticals USA, Inc. ("Teva") [Member] | Milestone Two [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Contingent Liability Not Recognized   $ 15,000        
Teva Pharmaceuticals USA, Inc. ("Teva") [Member] | Acquired ANDA Intangible Assets [Member]            
Fair Values Inputs Assets Quantitative Information [Line Items]            
Payments to Acquire Intangible Assets       $ 2,500    
Finite-Lived Intangible Assets, Gross       $ 2,500    
Finite-Lived Intangible Asset, Useful Life       10 years    
Acquisition Costs Capitalized       $ 10    
Fair Values Inputs Discount Rate       15.00%